Autosomal dominant and recessive forms of dystrophic epidermolysis bullosa (DEB) result from mutations in the type VII collagen gene \((COL7A1)\). Although paradigms have emerged for genotype/phenotype correlation in DEB, some pathogenic mutations in \(COL7A1\), notably glycine substitutions within the type VII collagen triple helix, may lead to diagnostic difficulties, since certain glycine substitutions can result in either dominant or recessive mutant alleles. Delineation of glycine substitution mutations into two discrete groups, however, is made difficult by observations that, for some particular glycine substitutions in type VII collagen, the same mutation can result in both dominant and recessive disease. In this report we describe four further glycine missense mutations: \(p.Gly1483Asp\), \(p.Gly1770Ser\), \(p.Gly2213Arg\) and \(p.Gly2369Ser\), which can lead to either dominant or recessive DEB, and which result in a spectrum of clinical abnormalities. We also identify a further 30 new glycine substitution mutations that cause either dominant or recessive DEB, but not both. In screening the \(COL7A1\) gene for mutations in individuals with DEB our data highlight that delineation of glycine substitutions in type VII collagen has important implications for genetic counselling. Key words: blister; genodermatosis; mechanobullous; basement membrane; gene mutation.

(Accepted October 28, 2010.)

Acta Derm Venereol 2011; 91: 262–266.

John McGrath, Dermatology Research Laboratories, Floor 9 Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK. E-mail: john.mcgrath@kcl.ac.uk

All subtypes of dystrophic epidermolysis bullosa (DEB) result from mutations in the type VII collagen gene, \(COL7A1\) (1). Type VII collagen is the major component of anchoring fibrils at the dermal–epidermal junction and in DEB the anchoring fibrils show variable numerical and/or structural abnormalities, changes that lead to blistering beneath the lamina densa (2). In dominant forms of DEB, the pathogenic mutations typically involve heterozygous (dominant-negative) glycine substitution (GS) mutations within the type VII collagen triple helix (3–5). In contrast, the molecular pathology of recessive DEB usually comprises nonsense, frameshift or splice site mutations on both \(COL7A1\) alleles (3–5). However, some cases of recessive DEB also result from GS mutations, which may be silent when heterozygous, but pathogenic when inherited on both alleles or in \textit{trans} with another loss-of-function mutation in \(COL7A1\) (3, 6). As a result, distinguishing between some dominant and recessive GS mutations can be very difficult, which may have important implications for making accurate diagnoses and for giving appropriate genetic counselling. This challenge is compounded by reports that some specific GS mutations can underlie both dominant and recessive forms of DEB, thus creating diagnostic dilemmas and difficulties (7–15). In this report we add four further GS mutations that can lead to both dominant and recessive forms of DEB and discuss their clinical and genetic significance. These cases were identified in diagnostic \(COL7A1\) mutation screening performed in the UK National Diagnostic EB Laboratory in London, UK. In addition, we have tabulated all published GS mutations in type VII collagen, sub-dividing them into mixed-type (Table 1), dominant and recessive mutations (Tables SI and SII (available at http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1053)). These Tables also contain an additional previously unpublished 19 dominant and 15 recessive GS mutations that were disclosed during diagnostic screening within the UK National Diagnostic EB service. Collectively, this information expands the mutation database and helps to refine genotype-phenotype correlation. We believe that the collective data will provide a useful reference resource for other investigators and diagnostic laboratories.
PATIENTS AND METHODS

Patients

DNA samples from patients with clinically suspected or skin biopsy proven DEB and their parents (if available) were analysed at the Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory in London, UK. This laboratory was established in 2003 and provides a diagnostic service for EB serving the whole of the UK. Given the multi-cultural nature of the UK, patient ethnicities included white Caucasian, Middle-Eastern, South American, South-East Asian and Asian. Most DNA sequencing was performed as part of the patients’ routine clinical care, but for cases linked to separate research projects, DNA screening was undertaken with ethics’ committee approval (St Thomas’ Hospital Ethics’ Committee; 07/H0802/104) with informed consent and carried out in accordance with the principles of the Declaration of Helsinki.

Mutation detection

Genomic DNA was extracted from peripheral blood leukocytes using standard methods (16). COL7A1 mutation screening was performed by direct sequencing of all 118 exons and flanking introns of the COL7A1 gene, as described previously, using an ABI 3100 sequencer (17). Mutations were verified by bi-directional sequencing and restriction endonuclease digestions, where possible.

RESULTS AND DISCUSSION

Dominant and recessive mutation: p.Gly1483Asp

The mutation p.Gly1483Asp was identified in four Kuwaiti individuals with different forms of DEB. A 7-year-old girl was diagnosed with bullous disease of the newborn (BDN) based on a history of generalized blistering at birth, which healed with minimal scarring and only occasional milia. The frequency of blistering decreased with age and had completely ceased by the age of 4 months. No subsequent blistering occurred. She was shown to be heterozygous for p.Gly1483Asp; identification of this dominant mutation was published in 2009 (18). However, a seemingly unrelated 16-month-old Kuwaiti child was found to be homozygous for this mutation. Fragility of the skin was noted soon after birth, with spontaneous blistering on the hands, trunk and extremities, which healed with minimal scarring but some milia formation. A few oral erosions and occasional periangual blistering were also present. There was some reduction in blistering severity with age, but new lesions continued to develop. The underlying diagnosis therefore was mild generalized recessive DEB. Neither of his parents, who were both shown to be heterozygous for this GS, had any clinical abnormalities. Two further individuals, a 17-year-old brother and a 23-year-old sister of Kuwaiti origin, who were not known to be related to the other cases, had generalized blistering at birth with recurrent oral ulcers. There was persistent skin fragility and oral erosions with gingival inflammation. Scattered allopapuloid lesions were noted on the chest, trunk and upper back. Nail dystrophy with loss of several fingernails and toenails was present, consistent with moderately severe generalized recessive DEB. Both individuals were homozygous for p.Gly1483Asp. Their parents were heterozygous carriers of this GS mutation but were clinically unaffected with no blistering, milia, abnormal scarring or nail dystrophy.

Dominant and recessive mutation: p.Gly1770Ser

The mutation p.Gly1770Ser also resulted in a variable phenotype (Fig. 1). This mutation has not been reported previously, although a substitution by a different amino acid, p.Gly1770Asp, on one allele has been found in a case of autosomal dominant EB pruriginosa (18). In a Pakistani family three children were observed to have generalized skin fragility with oral erosions. Wound healing was poor and scarring ensued. The features were consistent with severe generalized recessive DEB. Of these three affected individuals, two subjects (aged 1 year and 4 years) were brothers, whereas the other (aged 9 months) was a distant cousin. All three children were shown to be homozygous for p.Gly1770Ser, consistent with this being a recessive GS. However the parents of the two affected brothers both showed phenotypic abnormalities. Their DNA revealed heterozygosity for p.Gly1770Ser. The heterozygous father had nail dystrophy, but no skin blistering, whereas the heterozygous mother had nail dystrophy, blistering and inflammation on her shins consistent with pretibial DEB. Thus in these individuals heterozygosity for p.Gly1770Ser appeared to be acting as a dominant mutation with features of nail dystrophy or pretibial dominant DEB. By contrast the parents of the affected 9-month-old child were also heterozygous for p.Gly1770Ser, but neither of them had any phenotypic abnormalities. Thus, in both these individuals this particular GS appeared to function as a recessive allele that was silent in the heterozygous state.

Dominant and recessive mutation: p.Gly2213Arg

The mutation p.Gly2213Arg can also be associated with dominant or recessive forms of DEB (Fig. 2). A 45-year-old British woman with blistering and itching affecting the lower legs since the age of 37 years had scattered blisters and prurigo-like lesions on her shins consistent with a diagnosis of EB pruriginosa. DNA screening showed heterozygosity for the GS p.Gly2213Arg, but no other mutation was identified, leading to the diagnosis of a dominant form of dominant DEB; details of this case have been published previously (18). However, an unrelated 24-year-old British man was also shown to possess this mutation. He had generalized blistering affecting the skin, eyes and oral mucosa with some scarring. The phenotype was consistent with moderately severe generalized recessive DEB. DNA screening showed heterozygosity
for p.Gly2213Arg, but this mutation had been inherited in trans with the frameshift mutation c.4918delG (p.Gly1640fsX69), consistent with recessive DEB. Neither of his parents, including the carrier of the GS, had any clinical abnormalities.

Dominant and recessive mutation: p.Gly2369Ser

The mutation p.Gly2369Ser can also result in dominant or recessive DEB. A 49-year-old Pakistani man had a history of blistering and scarring with itching affecting his forearms, shins, hands and feet; he also had nail dystrophy. Examination showed extensive lichenified prurigo-like lesions consistent with EB pruriginosa. DNA screening showed heterozygosity for the mutation p.Gly2369Ser, but no other mutation was identified and he was therefore considered to have dominant DEB, details, of which were reported previously (19). However, this mutation was also detected in an unrelated 6-year-old British girl who presented with generalized skin fragility with scattered blisters, especially around the ankles and knees; blistering also affected the oral mucosa. Progressive flexion contractures and webbing of her fingers were present, consistent with severe generalized recessive DEB. DNA screening revealed homozygosity for the mutation p.Gly2369Ser, confirming a recessive form of DEB. Her parents were both shown to be heterozygous carriers of this mutation, but neither had any clinical abnormalities, including signs of nail dystrophy, in contrast to the previously reported heterozygous individual.

Database of dominant and recessive GS mutations in type VII collagen

In this study we noted that some GS mutations in type VII collagen (p.Gly1483Asp, p.Gly1770Ser, p.Gly2213Arg and p.Gly2369Ser) may function in a dominant or recessive manner. This observation has also been reported for some other GS mutations, namely p.Gly1595Arg, p.Gly1815Arg, p.Gly2028Arg, p.Gly2028Trp, p.Gly2210Val, p.Gly2251Glu, p.Gly2287Arg and p.Gly2351Arg (7–15) (Table I). With regards to the previous reports, it is clear that, similar to the new mutations we identified, these atypical GS mutations are associated with diverse clinical and genetic consequences.

Collectively, these type VII collagen GS mutations that can underlie both dominant and recessive forms of DEB (Table I) comprise less than 10% of all GS within this particular collagen, the remainder being almost evenly split between dominant and recessive cases of DEB (see Tables SI and SII). A key question, however, is whether there is anything...
specific about the nature of a particular GS in type VII collagen that might have implications for the genotype and genetic counselling. Such characteristics might include: the nature of the substituted amino acid, the position of the GS in the triple helix, the proximity of the GS to the non-helical hinge region in the triple helix or the non-collagenous NC-1 or NC-2 domains, unpredicted consequences of the nucleotide substitution on splicing, as well as biochemical changes to the collagen affecting helix formation, protein folding, thermal stability, intracellular transport, secretion, and assembly into anti-parallel dimers or anchoring fibrils (6–8, 10, 11, 20–29). Assessment of the data in Tables SI and SII, however, shows no clear indication of which particular mutations are likely to be dominant or recessive, an interpretation reinforced by the identification of the 12 specific type VII collagen GS mutations that can be either dominant or recessive (Table I). In addition, amino acid substitutions in glycines 1522, 2009, 2061, 2073, 2233, 2366, 2623 and 2719 may all cause dominant or recessive disease, but with different substituting residues in the different disease subtypes. There does not appear to be any specific differences in males or females with regards to phenotype. Clinical heterogeneity within a specific genotype may reflect influences such as functional polymorphisms within genes such as the matrix metalloproteinase 1 promoter (30), but this cannot impact on whether the inheritance pattern is in fact dominant or recessive.

For investigators screening for COL7A1 gene pathology who identify a GS mutation, we recommend cross-referencing with the data presented in our three Tables. This information is likely to provide an accurate guide to interpreting the genotype, although it is possible that further patient data may shift more of the GS mutations from either the dominant or recessive lists into the group of mixed GS mutations. In all cases of DEB, we recommend comprehensive screening of the COL7A1 gene and not curtailing the sequencing work once a “possible” dominant GS mutation has been identified. Such an approach is likely to reveal more examples of recessive GS mutations as well as mixed-type pathology.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Exon</th>
<th>Recessive</th>
<th>Diagnosis</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDEB-na, asymptomatic carrier, DDEB-pt</td>
<td>61</td>
<td>p.Gly1770Ser/p.Gly1770Ser</td>
<td>RDEB-sev gen</td>
<td>This paper</td>
</tr>
<tr>
<td>DDEB-gen, DDEB-pr, DDEB-na</td>
<td>73</td>
<td>p.Gly2028Arg/p.Cys2827Stop</td>
<td>RDEB-sev gen</td>
<td>(10, 12, 13, 14)</td>
</tr>
<tr>
<td>DDEB-gen</td>
<td>73</td>
<td>p.Gly2028Arg</td>
<td>RDEB-O</td>
<td>(12)</td>
</tr>
<tr>
<td>DDEB-pr</td>
<td>87</td>
<td>p.Gly2287Arg/p.Gly2287Arg</td>
<td>RDEB-O</td>
<td>(9)</td>
</tr>
</tbody>
</table>

*Inherited with the missense mutation p.Arg2791Trp on the same allele (15).

ACKNOWLEDGEMENTS

N.A. is a clinical research fellow supported by the Dystrophic Epidermolysis Bullosa Research Association (Debra, UK). We acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust.

The authors declare no conflicts of interest.

REFERENCES

6. Shimizu H, McGrath JA, Christiano AM, Nishikawa T,


